EX VIVO MULTIMODAL SPECTROSCOPY OF BREAST CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 我们开发了结合拉曼光谱、漫反射光谱和本征荧光光谱模式的MMS仪器。我们之前从两台提供拉曼信息的临床仪器获得的结果，以及漫反射光谱和本征荧光光谱的组合，使我们能够以高灵敏度和特异性诊断正常、纤维囊性病变、纤维腺瘤和浸润性导管癌病变。在新的临床体外研究中，所有三种模式的光谱信息都将通过多模式正视探头从新切除的乳房组织的同一位置收集。这项研究将在大学医院-病例医学中心的病理学病房进行，在部分和全部乳房切除术后半小时内进行。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We have developed the MMS instrument that combines Raman, diffuse reflectance and intrinsic fluorescence spectroscopy modalities. Our previous results obtained from two clinical instruments that provide information on Raman and combination of diffuse reflectance and intrinsic fluorescence spectroscopies, respectively, have allowed us to diagnose normal, fibrocystic change, fibroadenoma and infiltrating ductal carcinoma lesions with high sensitivity and specificity. In the new clinical ex vivo study spectral information from all three modalities will be collected from the same site of the freshly excised breast tissue via multimodal front-viewing probe. This study will be conducted in the pathology suite in the University Hospitals-Case medical center within half an hour of excision during partial and whole mastectomy.